// App-Quantinova.ai

1068 : A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.

Researchers

Presenter

  • Romualdo Barroso-Sousa

Principal Investigators

  • Hao Guo

  • William Thomas Barry

  • Arlindo R. Ferreira

  • Rebecca Rees

  • Eric P. Winer

  • Nikhil Wagle

  • Sara M. Tolaney

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Oncology Division, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Locations

  • United States

  • Portugal

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

  • Circulating DNA

Drug/Treatment

  • Palbociclib

  • Everolimus

  • Exemestane

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved